Celebrex and Metformin for Postoperative Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This prospective trial aims to compare the role of celebrex alone, metformin alone, and
celebrex plus metformin in preventing HCC recurrence after hepatic resection.